NCT07334145

Effect of SGLT2 Inhibitors on Anemic CKD Patients

Effect of SGLT2 Inhibitors On Anemia in Patients With Chronic Kidney Disease (CKD)

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 60 (estimated)
• Sponsor: Sohag University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD

Conditions

• Anemia in CKD Patients

Interventions

Type	Name	Description
DRUG	SGLT2 inhibitor	prescription of SGLT2 inhibitors like dapagliflozin or empagliflozin to anemic CKD patients stage 1\_4

Timeline

• Start date: 2026-01-01
• Primary completion: 2026-07-01
• Completion: 2026-09-01
• First posted: 2026-01-12
• Last updated: 2026-01-14

Locations

1 site across 1 country: Egypt

Regulatory

• FDA-regulated drug study